Pharvaris (PHVS) announced that the European Commission has granted orphan designation to its investigational drug, deucrictibant, for the treatment of bradykinin-mediated angioedema. The U.S. FDA previously granted orphan drug designation to deucrictibant for the treatment of bradykinin-mediated angioedema in March 2022.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PHVS: